Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders

Abstract

Get full access to this article

View all access options for this article.

References

Berger

JR.

Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 2017; 12: 59–63.

Aoyama

Mori

Uzawa

, et al. Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: Elevations along with fingolimod treatment duration. J Neurol 2018; 265: 1145–1150.

Kim

Hyun

Jeong

, et al. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder. J Neurol 2015; 262: 696–700.

Wingerchuk

Banwell

Bennett

, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–179.

Bozic

Subramanyam

Richman

, et al. Anti-JC virus (JCV) antibody prevalence in the JCV epidemiology in MS (JEMS) trial. Eur J Neurol 2014; 21: 299–304.